trending Market Intelligence /marketintelligence/en/news-insights/trending/LIg2gqqyXzkaWqogBq91YQ2 content esgSubNav
In This List

AstraZeneca's Imfinzi lung cancer combo fails late-stage study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AstraZeneca's Imfinzi lung cancer combo fails late-stage study

AstraZeneca PLC said a late-stage trial of a combination treatment with Imfinzi failed its primary goal of extending the lives of certain lung cancer patients.

The trial, dubbed Neptune, evaluated Imfinzi, or durvalumab, in combination with tremelimumab against standard chemotherapy in patients with previously untreated advanced non-small cell lung cancer and high levels of gene mutations.

The study showed the Imfinzi-tremelimumab combination failed to extend patients' lives compared to platinum-based chemotherapy.

The safety and tolerability profile for the combination of Imfinzi and tremelimumab was consistent with previous trials.

The Cambridge, U.K.-based drugmaker will present the full results of the trial at a forthcoming medical meeting.

Imfinzi belongs to a class of drugs known as immunotherapy, which boost the body's immune system to fight cancer.